Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
29 participants
INTERVENTIONAL
2025-10-01
2030-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MRI-guided Locoregional SBRT Prostate Program
NCT07132073
MRI-guided Ultrahypofractionated SBRT Prostate Program
NCT07132658
High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
NCT06982469
Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Radiosurgery
NCT01766492
Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer
NCT04067570
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MRI-guided Brachytherapy and Salvage SBRT Program
Brachytherapy and MR-guided SBRT
Brachytherapy and MR-Guided SBRT
HDR Brachytherapy followed by MR-guided SBRT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brachytherapy and MR-Guided SBRT
HDR Brachytherapy followed by MR-guided SBRT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Distant Metastases
3. Isolated nodal relapses
4. Prior Irradiation to the IPBR area
5. Multicentric IPBRs
6. Life expectancy of less than 5 years or inability to tolerate and comply with an HDR procedure
3. No prior radiation therapy to the target areas;
4. Karnofsky performance status \> 70 with medical condition not contraindicating treatment with radical intent including maximal TURBT and concomitant chemotherapy;
5. WBC equal or greater than 3500 mm3; platelet count equal or greater than 135000 mm3; hemoglobin equal or greater than 10 gr/L; BUN equal or less than 20; serum creatinine equal or less than 2.0.
6. Ability to undergo MRI scanning.
18 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinica Universidad de Navarra, Universidad de Navarra
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rafael Martínez-Monge, M.D.
Role: PRINCIPAL_INVESTIGATOR
Clínica Universidad de Navarra
Marta Gimeno-Morales, M.D.
Role: PRINCIPAL_INVESTIGATOR
Clínica Universidad de Navarra
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024.224
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.